Respiratory Syncytial Virus Infection
📧 Sign up to get email alerts when something new happens for Respiratory Syncytial Virus Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-01-02Clinical Trial Update: A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older [Phase 1, Phase 2]
Phase 1/2 study of RSV preF-based vaccine formulations in adults aged 60+ was terminated with results posted in January 2024.
-
CLINICAL_TRIALS trial_result · 2023-12-21Clinical Trial Update: Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above [Phase 3]
Phase 3 trial update evaluating immunogenicity, safety, reactogenicity, and persistence of an investigational RSV vaccine in adults 60 years…
-
CLINICAL_TRIALS trial_result · 2023-11-29Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) [Phase 1, Phase 2]
This phase 1/2 trial update reports safety, tolerability, and pharmacokinetics data for Clesrovimab (MK-1654) in infants with respiratory in…
-
CLINICAL_TRIALS trial_result · 2023-10-30Clinical Trial Update: A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects [Phase 2]
Phase 2 trial updates the assessment of EDP-938 for treating acute upper respiratory tract infection caused by Respiratory Syncytial Virus; …
-
CLINICAL_TRIALS trial_result · 2023-10-04Clinical Trial Update: A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection [Phase 3]
Phase 3 trial of an Ad26.RSV.preF-based vaccine for respiratory syncytial virus infection prevention in adults aged 18–59 (including high-ri…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection [Phase 2]
Phase 2 trial to evaluate safety and antiviral activity of JNJ-53718678 in children aged 28 days to 3 years with respiratory syncytial virus…
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older [Phase 3]
Phase 3 trial assessing an Ad26.RSV.preF-based RSV vaccine with and without coadministration of a high-dose seasonal influenza vaccine in ad…
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older [Phase 1, Phase 2]
A Phase 1/2 clinical trial update evaluating the safety and immunogenicity of Ad26.RSV.preF and RSV preF Protein vaccine combinations, with …
-
CLINICAL_TRIALS trial_result · 2023-09-11Clinical Trial Update: A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old [Phase 3]
Phase 3 study assessing the immunogenicity of the Ad26.RSV.preF-based vaccine for respiratory syncytial virus in adults aged 60–75; results …
-
CLINICAL_TRIALS trial_result · 2023-09-06Clinical Trial Update: A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years [Phase 3]
A Phase 3 study of Janssen's Ad26.RSV.preF-based RSV vaccine regimen in adults aged 60-75 has completed and posted its results.
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above [Phase 3]
Phase 3 efficacy study of GlaxoSmithKline's investigational RSV vaccine in adults aged 60 years and older has completed. Results have been p…
-
CLINICAL_TRIALS trial_result · 2023-08-03Clinical Trial Update: Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children [Phase 1]
Phase 1 study assessing the infectivity, safety, and immunogenicity of the RSV vaccine RSV 6120/∆NS2/1030s in RSV-seropositive children and …
-
CLINICAL_TRIALS trial_result · 2023-07-24Clinical Trial Update: A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older [Phase 2]
Phase 2 trial of Janssen's Ad26.RSV.preF-based vaccine regimen for preventing RSV-mediated lower respiratory tract disease in adults aged 65…
-
CLINICAL_TRIALS trial_result · 2023-07-21Clinical Trial Update: Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults [Phase 2]
Phase 2a study evaluating MVA-BN-RSV vaccination with RSV challenge in healthy adults has completed.
-
CLINICAL_TRIALS trial_result · 2023-06-23Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age [Phase 1, Phase 2]
A Phase 1/2 study evaluating the safety, tolerability and immunogenicity of the investigational RSV vaccine candidate Ad26.RSV.preF in adult…
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection [Phase 2]
A Phase 2 study of Rilematovir (JNJ-53718678) in adult outpatients with respiratory syncytial virus infection was terminated; results have b…
-
CLINICAL_TRIALS trial_result · 2023-04-10Clinical Trial Update: A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) [Phase 3]
Phase 3 study of Rilematovir in infants, children, and neonates hospitalized with RSV-related respiratory infection was terminated with resu…
-
CLINICAL_TRIALS trial_result · 2023-02-15Clinical Trial Update: A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above [Phase 3]
A Phase 3 trial evaluated three lots of an investigational RSV vaccine in adults aged 60+, with results posted after completion.
-
CLINICAL_TRIALS trial_result · 2022-12-19Clinical Trial Update: A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women [Phase 2]
Phase 2 clinical trial evaluating an RSV vaccine alone or with a Tdap vaccine, followed by a second RSV dose, in healthy non-pregnant women;…
-
CLINICAL_TRIALS trial_result · 2022-11-30Clinical Trial Update: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age [Phase 1, Phase 2]
This clinical trial update reports results from Phase 1/2 studies assessing safety, reactogenicity, and immunogenicity of the Ad26.RSV.Pre-F…
-
CLINICAL_TRIALS trial_result · 2022-08-04Clinical Trial Update: Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine [Phase 2]
Phase 2 human challenge study evaluating MV-012-968 vaccine for respiratory syncytial virus (RSV) infection has completed.
-
CLINICAL_TRIALS trial_result · 2022-07-19Clinical Trial Update: A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults [Phase 3]
A Phase 3 clinical trial evaluating an RSV F vaccine in older adults has completed.
-
CLINICAL_TRIALS trial_result · 2022-06-29Clinical Trial Update: Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study [Phase 2]
An extension Phase 2 trial evaluating safety and immunogenicity of a revaccination dose of the RSVPreF3 OA investigational vaccine in adults…
-
CLINICAL_TRIALS trial_result · 2022-06-08Clinical Trial Update: A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease [Phase 2]
A Phase 2 infant study evaluated early diagnosis of Respiratory Syncytial Virus and the evaluation of JNJ-53718678 in RSV acute respiratory …
-
CLINICAL_TRIALS trial_result · 2022-05-27Clinical Trial Update: Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year. [Phase 2]
A Phase 2 trial assessing safety and immunogenicity of the RSV-F vaccine in older adults previously treated with the same vaccine or placebo…